Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Maryann Shango"'
Autor:
Mark S. Kaminski, Shannon A. Carty, Maryann Shango, Anthony J Scott, Tycel Phillips, Molly Tokaz, Ryan A. Wilcox, Arul M. Chinnaiyan, Sumana Devata
Publikováno v:
Leukemialymphoma. 62(4)
Successful treatment of relapsed/refractory and rare subtypes of lymphomas remains a therapeutic challenge. Though the use of tumor profiling is increasing, little is described about how providers ultimately utilize this information in clinical decis
Autor:
Sumana Devata, Maryann Shango, Paul M. Barr, Ryan A. Wilcox, Jennifer E Amengual, Jason B. Kaplan, Stephen D. Smith, Paolo Caimi, Marcus Geer, Philip S. Boonstra, Evan Rosenbaum, Emily Roberts, Mark S. Kaminski, Hashim Abbas, Brian T. Hill, Emily Lin, Brian G. Till, Alex F. Herrera, Tycel Phillips, Deborah M. Stephens
Publikováno v:
Br J Haematol
Intravascular large B-cell lymphoma (IVLBCL) is a rare entity, with a generally aggressive course that may vary based on geographic presentation. While a United States (US) registry study showed relatively good outcomes with IVLBCL, clinicopathologic
Autor:
Maryann Shango, Rashmi Chugh, Monika Leja, Brittany L. Siontis, Scott M. Schuetze, Laurence H. Baker, Jonathan B. McHugh, Lili Zhao
Publikováno v:
Sarcoma
Sarcoma, Vol 2019 (2019)
Sarcoma, Vol 2019 (2019)
Introduction. Primary cardiac sarcoma (PCS) has a poor prognosis compared to other sarcomas due to late presentation, challenging resection, incidence of metastases, and limited efficacy of systemic therapies.Methods. A medical record search engine w
Autor:
Bo Wen, Jeremy Felton, James M. Rae, Liam Riddle, Shawna Kraft, Danielle Karsies, Maryann Shango, Melissa A. Reimers, Stephanie Daignault-Newton, Bruce G. Redman, Ajjai Alva, Christina L. Gersch, Rachel Dedinsky
Publikováno v:
Investigational new drugs. 37(2)
Background Pazopanib is approved for metastatic renal cell carcinoma (RCC). We assessed the safety and efficacy of pazopanib with a low fat meal (LFM)
Autor:
Tycel Phillips, Maryann Shango, Mark S. Kaminski, Molly Tokaz, Arul M. Chinnaiyan, Anthony J Scott, Ryan A. Wilcox, Shannon A. Carty, Sumana Devata
Publikováno v:
Journal of Clinical Oncology. 37:e14645-e14645
e14645 Background: Despite the increasing availability of targeted and novel therapies, successful treatment of many relapsed/refractory lymphomas remains a challenge. Tumor sequencing is becoming an increasingly available technique to identify poten
Autor:
R. Brusovansky, Paul R. Lephart, Jack D. Sobel, Keith S. Kaye, Dror Marchaim, Miriam T. Levine, Maryann Shango, Robert A. Akins, Kayoko Hayakawa, T. Lazarovitch
Publikováno v:
Infection. 41:329-337
The nomenclature of Streptococcus bovis has changed. The study aims were to examine and compare the clinical characteristics and outcomes of infections based on the new taxonomy and the genetic relatedness of strains. Bacteremic cases from 2004 to 20
Autor:
Suchitha Bheemreddy, Christopher Bogan, Keith S. Kaye, Kayoko Hayakawa, Christopher Blunden, Jason M. Pogue, Federico Perez, Sorabh Dhar, Teena Chopra, Jessie Swan, Dror Marchaim, Ashish Bhargava, Robert A. Bonomo, Maryann Shango, Paul R. Lephart
Publikováno v:
Infection Control & Hospital Epidemiology. 33:817-830
Background.Carbapenem-resistant Enterobacteriaceae (CRE) are rapidly emerging worldwide. Control group selection is critically important when analyzing predictors of antimicrobial resistance. Focusing on modifiable risk factors can optimize preventio
Autor:
Maryann Shango, Melissa A. Reimers, Liam Riddle, Rachel Dedinsky, Ajjai Alva, Bruce G. Redman, Stephanie Daignault, Bo Wen
Publikováno v:
Journal of Clinical Oncology. 36:683-683
683 Background: Pazopanib, a highly lipophilic standard first-line therapy for metastatic RCC, is conventionally taken in a fasting state but has significant gastrointestinal toxicities and 96% of ingested drug is fecally excreted, with major financi
Publikováno v:
Journal of Clinical Oncology. 35:e23169-e23169
e23169 Background: Personalized therapy through the identification of targetable mutations within individual tumors has increasingly become a focus in the management of patients (pts) with relapsed/refractory malignancy. To better understand how this
Publikováno v:
The American Journal of dermatopathology. 34(7)
It is known that human keratinocytes (KCs) express Toll-like receptors (TLRs). However, published reports conflict regarding TLR expression in cutaneous T-cell lymphoma patient's KCs. To define the pattern of expression and detect any differences of